{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:44Z","timestamp":1791612644961,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.kint.2016.09.048","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T06:18:14Z","timestamp":1483683494000},"page":"566-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Membranous nephropathy: integrating basic science into improved clinical management"],"prefix":"10.1016","volume":"91","author":[{"given":"Daniel C.","family":"Cattran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Brenchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2016.09.048_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-6386(00)70316-7","article-title":"Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia\/New Zealand: results from an international comparative study","volume":"35","author":"Maisonneuve","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.09.048_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ki.2013.512","article-title":"Utility of renal biopsy in\u00a0the clinical management of renal disease","volume":"85","author":"Dhaun","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/kisup.2012.12","article-title":"Abstract","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2016.09.048_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidence-based therapy","volume":"27","author":"McQuarrie","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib6","first-page":"158","article-title":"Regional program for the study of glomerulonephritis. Central Committee of the Toronto Glomerulonephritis Registry","volume":"124","year":"1981","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.kint.2016.09.048_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2215\/CJN.00710805","article-title":"Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study","volume":"1","author":"Swaminathan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib8","unstructured":"Geddes C, Walbaum C, MacGreger M, et al. Scottish Renal Association Annual Report 2015, Section N on Renal Biopsy Registry. Available at: http:\/\/www.srr.scot.nhs.uk\/Contacts\/Biopsy-registry-steering-group.html. Accessed November 2016."},{"key":"10.1016\/j.kint.2016.09.048_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000370272","article-title":"UK renal registry 17th annual report: Chapter 2: UK Renal Replacement Therapy Prevalence In 2013: National and Centre-specific Analyses","volume":"129","author":"Rao","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2016.09.048_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/ndt\/gfn677","article-title":"Centre variation in incidence, indication and diagnosis of adult native renal biopsy in Scotland","volume":"24","author":"McQuarrie","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib12","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization","volume":"270","author":"Ancian","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.09.048_bib13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(79)92118-4","article-title":"Strong association between idiopathic membranous nephropathy and HLA-DRW3","volume":"2","author":"Klouda","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.09.048_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-0039.1989.tb01741.x","article-title":"A\u00a0DQA1 allele is strongly associated with idiopathic membranous nephropathy","volume":"34","author":"Vaughan","year":"1989","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.kint.2016.09.048_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA 2 R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J\u00a0Am SocNephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib17","doi-asserted-by":"crossref","unstructured":"Sekula P, Li Y, Stanescu HC, et\u00a0al. Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies [e-pub \u2013of print]. Nephrol Dial Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw001. Accessed November 2016.","DOI":"10.1093\/ndt\/gfw001"},{"key":"10.1016\/j.kint.2016.09.048_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.kint.2016.09.048_bib19","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1074\/jbc.274.11.7043","article-title":"Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor","volume":"274","author":"Cupillard","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.09.048_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.febslet.2015.02.016","article-title":"C-type lectin-like domain and fibronectin-like type II domain of phospholipase A(2) receptor 1 modulate binding and migratory responses to collagen","volume":"589","author":"Takahashi","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kint.2016.09.048_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib22","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1074\/jbc.M113.512780","article-title":"Complex determinants in specific members of the mannose receptor family govern collagen endocytosis","volume":"289","author":"Jurgensen","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.09.048_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/eci.12292","article-title":"Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen","volume":"44","author":"Skoberne","year":"2014","journal-title":"EurJ Clin Invest"},{"key":"10.1016\/j.kint.2016.09.048_bib24","first-page":"435A","article-title":"The effect of anti-PLA2R autoantibodies on human podocytes in\u00a0vitro","volume":"26","author":"Fresquet","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib25","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1681\/ASN.2015080953","article-title":"Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","author":"Qin","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib26","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to pla2r associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib28","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2016.09.048_bib30","first-page":"1437","article-title":"Circulating antibodies to alpha-enolase and phospholipase A receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy","author":"Kimura","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.02170312","article-title":"Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy","volume":"7","author":"Murtas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ki.1989.162","article-title":"Urinary excretion of C5b-9 reflects disease activity in passive Heymann nephritis","volume":"36","author":"Pruchno","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib33","first-page":"185","article-title":"Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats","volume":"135","author":"Baker","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2016.09.048_bib34","first-page":"7","article-title":"Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy","volume":"60","author":"Cattran","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib35","first-page":"397","article-title":"The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy","volume":"8","author":"Coupes","year":"1993","journal-title":"Nephrol DialTransplant"},{"key":"10.1016\/j.kint.2016.09.048_bib36","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ki.1995.496","article-title":"Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy","volume":"48","author":"Kon","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ki.1991.242","article-title":"Elevated urinary excretion of the C5b-9 complex in membranous nephropathy","volume":"40","author":"Schulze","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fimmu.2016.00157","article-title":"Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy","volume":"7","author":"Borza","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2016.09.048_bib39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol DialTransplant"},{"key":"10.1016\/j.kint.2016.09.048_bib40","doi-asserted-by":"crossref","unstructured":"Bally S, Debiec H, Ponard D, et al. Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency [e-pub ahead of print]. J Am Soc Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2015101155. Accessed November 2016.","DOI":"10.1681\/ASN.2015101155"},{"key":"10.1016\/j.kint.2016.09.048_bib41","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.09.048_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2016.09.048_bib43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00467-013-2574-9","article-title":"Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy","volume":"28","author":"Cossey","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000440983","article-title":"Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy","volume":"42","author":"Kim","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib46","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1038\/srep08803","article-title":"Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis","volume":"5","author":"Dai","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2016.09.048_bib47","first-page":"469","article-title":"Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms","volume":"29","author":"Murtas","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib48","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.09.048_bib49","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib51","first-page":"793","article-title":"The natural history of membranous nephropathy in the West of Scotland","volume":"60","author":"MacTier","year":"1986","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib52","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ndt\/gfv399","article-title":"PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians","volume":"31","author":"Ramachandran","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2016.09.048_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ndt\/5.suppl_1.37","article-title":"The natural history and therapy of idiopathic membranous nephropathy","volume":"5","author":"Ponticelli","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib55","first-page":"127","article-title":"Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted?","volume":"41","author":"Honkanen","year":"1994","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib56","doi-asserted-by":"crossref","first-page":"e110681","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA 2 R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.09.048_bib57","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib58","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib59","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0891-6632(91)90021-G","article-title":"Structural-functional relationships in type I insulin-dependent diabetes mellitus in humans","volume":"5","author":"Lane","year":"1991","journal-title":"J\u00a0Diabet Complications"},{"key":"10.1016\/j.kint.2016.09.048_bib62","first-page":"617","article-title":"Renal function and functional reserve in healthy elderly individuals","volume":"20","author":"Esposito","year":"2006","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib63","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase a2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib64","doi-asserted-by":"crossref","unstructured":"Kanigicherla DAK, Short CD, Roberts SA, et al. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy [e-pub ahead of print]. Nephrol Dial Transplant. pii: gfv435. Accessed November 26, 2016.","DOI":"10.1093\/ndt\/gfv435"},{"key":"10.1016\/j.kint.2016.09.048_bib65","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A\u00a010-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib66","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"10","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2016.09.048_bib67","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","article-title":"Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy","volume":"33","author":"Laluck","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.09.048_bib68","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfs379","article-title":"Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study","volume":"28","author":"Irazabal","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib70","doi-asserted-by":"crossref","unstructured":"Cattran DC, Kim ED, Reich H, et al., for the Toronto Glomerulonephritis Registry Group. Membranous nephropathy: quantifying remission duration on outcome [e-pub head of print]. J Am Soc Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2015111262. Accessed December 19, 2016.","DOI":"10.1681\/ASN.2015111262"},{"key":"10.1016\/j.kint.2016.09.048_bib71","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib73","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.09.048_bib74","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: an update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kint.2016.09.048_bib76","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Updates in renal medicine 1 Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.09.048_bib77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ki.2010.156","article-title":"Glomerular disease: why is there a dearth of high quality clinical trials?","volume":"78","author":"Leaf","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib80","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib81","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib82","doi-asserted-by":"crossref","first-page":"c145","DOI":"10.1159\/000324762","article-title":"Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated","volume":"119","author":"Barnes","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2016.09.048_bib83","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A\u00a0randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0971-4065.136884","article-title":"Study of hypothalamic pituitary adrenal axis in patients of membranous nephropathy receiving modified Ponticelli regimen","volume":"25","author":"Ramachandran","year":"2015","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib85","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib86","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib87","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib88","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.09.048_bib89","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.09.048_bib90","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.09.048_bib92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A\u00a0Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2016.09.048_bib93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A\u00a0European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2016.09.048_bib94","doi-asserted-by":"crossref","unstructured":"Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up [e-pub ahead of print]. J Am Soc Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2016040449. Accessed November 2016.","DOI":"10.1681\/ASN.2016040449"},{"key":"10.1016\/j.kint.2016.09.048_bib95","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ackd.2011.06.008","article-title":"Historical aspects of proteinuria","volume":"18","author":"Cattran","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2016.09.048_bib96","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A\u00a0randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.09.048_bib97","doi-asserted-by":"crossref","first-page":"e87816","DOI":"10.1371\/journal.pone.0087816","article-title":"Effects of melanocortin 1 receptor agonists in experimental nephropathies","volume":"9","author":"Lindskog Jonsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.09.048_bib98","doi-asserted-by":"crossref","first-page":"F846","DOI":"10.1152\/ajprenal.00231.2015","article-title":"Melanocortin 1 receptor agonist protects podocytes through catalase and rhoA activation","volume":"310","author":"Elvin","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2016.09.048_bib99","doi-asserted-by":"crossref","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","author":"van de Logt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.09.048_bib100","first-page":"668","article-title":"Eculizamab in the treatment of idiopathic membranous nephropathy","volume":"13","author":"Appel","year":"2002","journal-title":"35th Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib101","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A\u00a0pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.09.048_bib102","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.09.048_bib103","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1681\/ASN.2005010096","article-title":"Contrasting roles of complement activation and its regulation in membranous nephropathy","volume":"16","author":"Cunningham","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.09.048_bib104","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/eci.12545","article-title":"A\u00a0new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis","volume":"45","author":"M\u00fcller-Deile","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2016.09.048_bib105","unstructured":"Cattran DC, Brenchley P. Membranous nephropathy: thinking through\u00a0the therapeutic options. Nephrology Dialysis Transplantation, in press."},{"key":"10.1016\/j.kint.2016.09.048_bib106","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816306172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816306172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T17:40:41Z","timestamp":1658338841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253816306172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0085253816306172"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.09.048","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membranous nephropathy: integrating basic science into improved clinical management","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.09.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}